Low intensity ultrasound combination cancer therapies
US-2024226159-A9 · Jul 11, 2024 · US
Mutants PF4 polypeptides exhibiting an increased anti-angiogenic activity
US8940702B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8940702-B2 |
| Application number | US-201013386696-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 26, 2010 |
| Priority date | Jul 29, 2009 |
| Publication date | Jan 27, 2015 |
| Grant date | Jan 27, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention pertains to PF4 muteins which comprise a substitution at position 67, e.g. a L67H substitution, compared to the sequence of the wild-type PF4 protein. Such PF4 muteins exhibit an increased anti-angiogenie activity and a reduced affinity for proteoglycans compared to the wild-type PF4 protein.
First claim
Opening claim text (preview).
The invention claimed is: 1. A polypeptide selected from the group consisting of SEQ ID Nos.:4, 5, 6, 7, or 8, or a fragment of at least 10 consecutive amino acids of said polypeptide, wherein said fragment includes positions 58 to 67 of SEQ ID NO:2. 2. The polypeptide according to claim 1 , wherein the leucine at position 67 of SEQ ID NO: 2 is replaced with histidine. 3. The polypeptide according to claim 1 , wherein said polypeptide diffe…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8940702B2 cover?
- The present invention pertains to PF4 muteins which comprise a substitution at position 67, e.g. a L67H substitution, compared to the sequence of the wild-type PF4 protein. Such PF4 muteins exhibit an increased anti-angiogenie activity and a reduced affinity for proteoglycans compared to the wild-type PF4 protein.
- Who is the assignee on this patent?
- Bikfalvi Andreas, Prats Herve, Quemener Cathy, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification C07K14/522. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).